JP5809288B2 - Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン - Google Patents
Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン Download PDFInfo
- Publication number
- JP5809288B2 JP5809288B2 JP2013545375A JP2013545375A JP5809288B2 JP 5809288 B2 JP5809288 B2 JP 5809288B2 JP 2013545375 A JP2013545375 A JP 2013545375A JP 2013545375 A JP2013545375 A JP 2013545375A JP 5809288 B2 JP5809288 B2 JP 5809288B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- compound
- hydrogen
- ring system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NNWPXEYFTXTCTE-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)CC1c(cc1)c(C)c(C)c1Nc1ncc(C(F)(F)F)c(Cl)n1)=O Chemical compound CC(C)(C)OC(N(CCC1)CC1c(cc1)c(C)c(C)c1Nc1ncc(C(F)(F)F)c(Cl)n1)=O NNWPXEYFTXTCTE-UHFFFAOYSA-N 0.000 description 1
- ZNOVHMLGEBACQE-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)CC1c(ccc(Nc1ncc(C(F)(F)F)c(Cl)n1)c1C)c1F)=O Chemical compound CC(C)(C)OC(N(CCC1)CC1c(ccc(Nc1ncc(C(F)(F)F)c(Cl)n1)c1C)c1F)=O ZNOVHMLGEBACQE-UHFFFAOYSA-N 0.000 description 1
- IRNPKPZWLHIVMH-HNNXBMFYSA-N CC(C)NC1=CC(C)(C)C=C([C@@H]2CNCCC2)C=C1 Chemical compound CC(C)NC1=CC(C)(C)C=C([C@@H]2CNCCC2)C=C1 IRNPKPZWLHIVMH-HNNXBMFYSA-N 0.000 description 1
- IRNPKPZWLHIVMH-OAHLLOKOSA-N CC(C)NC1=CC(C)(C)C=C([C@H]2CNCCC2)C=C1 Chemical compound CC(C)NC1=CC(C)(C)C=C([C@H]2CNCCC2)C=C1 IRNPKPZWLHIVMH-OAHLLOKOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196277 | 2010-12-21 | ||
| EP10196277.7 | 2010-12-21 | ||
| EP11189723 | 2011-11-18 | ||
| EP11189723.7 | 2011-11-18 | ||
| PCT/EP2011/073653 WO2012085126A1 (en) | 2010-12-21 | 2011-12-21 | Oxindolopyrimidine as igf1r receptor inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500295A JP2014500295A (ja) | 2014-01-09 |
| JP2014500295A5 JP2014500295A5 (https=) | 2015-02-05 |
| JP5809288B2 true JP5809288B2 (ja) | 2015-11-10 |
Family
ID=45507665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013545375A Active JP5809288B2 (ja) | 2010-12-21 | 2011-12-21 | Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8546443B2 (https=) |
| EP (1) | EP2655358B1 (https=) |
| JP (1) | JP5809288B2 (https=) |
| AR (1) | AR084444A1 (https=) |
| UY (1) | UY33817A (https=) |
| WO (1) | WO2012085126A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| BR112014029310A2 (pt) * | 2012-05-24 | 2018-06-26 | Cellzome Ltd | análogos da pirimidina heterocíclica como inibidores da tyk2 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP3696276A1 (en) | 2013-02-25 | 2020-08-19 | Novartis AG | Novel androgen receptor mutation |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US9862688B2 (en) * | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| AU2020337958A1 (en) | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| AU2024287547A1 (en) | 2023-07-07 | 2026-01-22 | Viridian Therapeutics, Inc. | Methods of treating chronic thyroid eye disease |
| WO2025045203A1 (zh) * | 2023-09-01 | 2025-03-06 | 葆元生物医药科技(杭州)有限公司 | 杂环化合物及其中间体和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PT1660458E (pt) | 2003-08-15 | 2012-04-27 | Novartis Ag | 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| WO2005023780A1 (en) | 2003-09-05 | 2005-03-17 | Pfizer Products Inc. | Selective synthesis of cf3-substituted pyrimidines |
| JP2007537230A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の処置用のピリミジン誘導体 |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| WO2006021548A1 (de) | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| ATE519759T1 (de) * | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
| DE102005016634A1 (de) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| US20080058312A1 (en) | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
| CA2648170A1 (en) | 2006-04-10 | 2007-10-18 | Boehringer Ingelheim International Gmbh | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
| CN101501023A (zh) | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
| CN101932580B (zh) | 2007-06-01 | 2013-05-22 | 葛兰素史密丝克莱恩有限责任公司 | 咪唑并吡啶激酶抑制剂 |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| CA2692379A1 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
-
2011
- 2011-12-19 US US13/329,615 patent/US8546443B2/en active Active
- 2011-12-19 UY UY0001033817A patent/UY33817A/es not_active Application Discontinuation
- 2011-12-20 AR ARP110104829A patent/AR084444A1/es unknown
- 2011-12-21 WO PCT/EP2011/073653 patent/WO2012085126A1/en not_active Ceased
- 2011-12-21 EP EP11810833.1A patent/EP2655358B1/en active Active
- 2011-12-21 JP JP2013545375A patent/JP5809288B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014500295A (ja) | 2014-01-09 |
| US20120329771A1 (en) | 2012-12-27 |
| UY33817A (es) | 2012-07-31 |
| WO2012085126A1 (en) | 2012-06-28 |
| AR084444A1 (es) | 2013-05-15 |
| EP2655358B1 (en) | 2014-11-19 |
| EP2655358A1 (en) | 2013-10-30 |
| US8546443B2 (en) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5809288B2 (ja) | Ｉｇｆ１ｒ受容体阻害薬としてのオキシインドールピリミジン | |
| JP5850952B2 (ja) | セリン／スレオニンキナーゼ阻害剤としての新しいアザインドリルフェニルスルホンアミド | |
| JP6128133B2 (ja) | Ｉｇｆ−１ｒ／ｉｒ阻害剤としての５，８−ジヒドロ−６ｈ−ピラゾロ［３，４−ｈ］キナゾリン | |
| JP5991974B2 (ja) | 新規アミノピラゾロキナゾリン | |
| US9428513B2 (en) | Triazolopyrazine | |
| JP6503386B2 (ja) | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 | |
| CA2956129C (en) | New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| CN104870448B (zh) | 三唑并吡嗪 | |
| EP2552905B1 (en) | B-Raf kinase inhibitors | |
| JP6577958B2 (ja) | スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用 | |
| JP5824068B2 (ja) | セリン／トレオニンキナーゼ阻害剤としての新規トリアゾリルフェニルスルホンアミド | |
| JP6488367B2 (ja) | ベンゾイミダゾール誘導体 | |
| JP2014503573A (ja) | セリン／スレオニンキナーゼ阻害薬としての新規ピリミド［５，４−ｄ］ピリミジルアミノフェニルスルホンアミド | |
| EP2571877A1 (en) | 1h - imidazo [4, 5 - c]quinolines | |
| WO2011131741A1 (en) | Heterocyclic carboxylic acid amides as pdk1 inihibitors | |
| TW201307321A (zh) | 新苯甲基羥吲哚嘧啶 | |
| TW201307315A (zh) | 作為絲胺酸／蘇胺酸激酶抑制劑之新穎三唑基苯基磺醯胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141211 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141211 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150806 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150812 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5809288 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |